SciSparc

SciSparc

SciSparc was founded in 2016 and is headquartered in Tel Aviv, Israel, under the leadership of CEO and CFO Oz Adler. The company operates as a specialty clinical-stage pharmaceutical firm focused on cannabinoid-based therapies. Its core intellectual property centers on a proprietary platform that combines cannabidiol (CBD) with low doses of palmitoylethanolamide (PEA), aiming to enhance the therapeutic effect of cannabinoids while minimizing side effects. The firm's pipeline targets central nervous system disorders, including Tourette Syndrome, for which its lead candidate SCI-110 has completed a Phase IIb clinical trial. It also pursues indications in Alzheimer’s disease and agitation, autism spectrum disorder, and status epilepticus, with SCI-210 for autism receiving FDA orphan drug designation. SciSparc advances its programs via direct development and through mergers and acquisitions, such as its merger with autoimmunity-focused Polyrizon Ltd. and the acquisition of an insomnia drug candidate from a German biotech. SciSparc is publicly traded on the Nasdaq Capital Market under the ticker SPRC, a notable listing that provides a window into its capital structure even as its dedicated workforce size remains unpublicized. The firm has not disclosed assets under management or a deployment figure, consistent with its operating-company status rather than that of a fund manager. The company's structural differentiator is its dual-track model — it develops CNS drugs directly while simultaneously acting as a consolidator of distressed or undervalued pharmaceutical assets. This approach allows it to build pipeline breadth without bearing the full cost of early-stage discovery for every candidate.